Meta-analysis of clinical trials with Interferon β and copolymerl in multiple sclerosis

L. La Mantia, M. Eoli, A. Salmaggi, V. Torri, R. D'Amico, Milanese C. Liberati

Research output: Contribution to journalArticle

Abstract

Recently published trials have shown that interferon beta and copolymer 1 are able to reduce relapse frequency in Multiple Sclerosis relapsing -remitting patients. The relative effectiveness of these treatments in modifying the natural course of the disease is not known. We performed a systematic review through Medline and Embase, of clinical trials with IfN -b and Cop-1 in MS, published between 1966 and 1996. Data contained in each article were collected by using a computerized data form, considering the following items: study design; clinical features of patients; outcome measures; results'evaluation; evaluation of study liability as suggested by drop-outs and withdrawals; side effects evaluation and toxicity data. The revised studies were analyzed and compared in term of common outcome measures. Odds ratio and confidence intervals will be calculated for each individual trial and for overall comparisons using the stratified logrank test. As check of the results a logistic model with each trial as controlling factor and the treatment as final factor will also beperformed.

Original languageEnglish
Pages (from-to)87
Number of pages1
JournalItalian Journal of Neurological Sciences
Volume18
Issue number4
Publication statusPublished - 1997

Fingerprint

Interferons
Multiple Sclerosis
Meta-Analysis
Clinical Trials
Outcome Assessment (Health Care)
Relapsing-Remitting Multiple Sclerosis
Interferon-beta
Logistic Models
Odds Ratio
Confidence Intervals
Recurrence
Therapeutics

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Meta-analysis of clinical trials with Interferon β and copolymerl in multiple sclerosis. / La Mantia, L.; Eoli, M.; Salmaggi, A.; Torri, V.; D'Amico, R.; Liberati, Milanese C.

In: Italian Journal of Neurological Sciences, Vol. 18, No. 4, 1997, p. 87.

Research output: Contribution to journalArticle

La Mantia, L. ; Eoli, M. ; Salmaggi, A. ; Torri, V. ; D'Amico, R. ; Liberati, Milanese C. / Meta-analysis of clinical trials with Interferon β and copolymerl in multiple sclerosis. In: Italian Journal of Neurological Sciences. 1997 ; Vol. 18, No. 4. pp. 87.
@article{976fba6f5e9c47ebabf9450362382c3f,
title = "Meta-analysis of clinical trials with Interferon β and copolymerl in multiple sclerosis",
abstract = "Recently published trials have shown that interferon beta and copolymer 1 are able to reduce relapse frequency in Multiple Sclerosis relapsing -remitting patients. The relative effectiveness of these treatments in modifying the natural course of the disease is not known. We performed a systematic review through Medline and Embase, of clinical trials with IfN -b and Cop-1 in MS, published between 1966 and 1996. Data contained in each article were collected by using a computerized data form, considering the following items: study design; clinical features of patients; outcome measures; results'evaluation; evaluation of study liability as suggested by drop-outs and withdrawals; side effects evaluation and toxicity data. The revised studies were analyzed and compared in term of common outcome measures. Odds ratio and confidence intervals will be calculated for each individual trial and for overall comparisons using the stratified logrank test. As check of the results a logistic model with each trial as controlling factor and the treatment as final factor will also beperformed.",
author = "{La Mantia}, L. and M. Eoli and A. Salmaggi and V. Torri and R. D'Amico and Liberati, {Milanese C.}",
year = "1997",
language = "English",
volume = "18",
pages = "87",
journal = "Italian Journal of Neurological Sciences",
issn = "0392-0461",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Meta-analysis of clinical trials with Interferon β and copolymerl in multiple sclerosis

AU - La Mantia, L.

AU - Eoli, M.

AU - Salmaggi, A.

AU - Torri, V.

AU - D'Amico, R.

AU - Liberati, Milanese C.

PY - 1997

Y1 - 1997

N2 - Recently published trials have shown that interferon beta and copolymer 1 are able to reduce relapse frequency in Multiple Sclerosis relapsing -remitting patients. The relative effectiveness of these treatments in modifying the natural course of the disease is not known. We performed a systematic review through Medline and Embase, of clinical trials with IfN -b and Cop-1 in MS, published between 1966 and 1996. Data contained in each article were collected by using a computerized data form, considering the following items: study design; clinical features of patients; outcome measures; results'evaluation; evaluation of study liability as suggested by drop-outs and withdrawals; side effects evaluation and toxicity data. The revised studies were analyzed and compared in term of common outcome measures. Odds ratio and confidence intervals will be calculated for each individual trial and for overall comparisons using the stratified logrank test. As check of the results a logistic model with each trial as controlling factor and the treatment as final factor will also beperformed.

AB - Recently published trials have shown that interferon beta and copolymer 1 are able to reduce relapse frequency in Multiple Sclerosis relapsing -remitting patients. The relative effectiveness of these treatments in modifying the natural course of the disease is not known. We performed a systematic review through Medline and Embase, of clinical trials with IfN -b and Cop-1 in MS, published between 1966 and 1996. Data contained in each article were collected by using a computerized data form, considering the following items: study design; clinical features of patients; outcome measures; results'evaluation; evaluation of study liability as suggested by drop-outs and withdrawals; side effects evaluation and toxicity data. The revised studies were analyzed and compared in term of common outcome measures. Odds ratio and confidence intervals will be calculated for each individual trial and for overall comparisons using the stratified logrank test. As check of the results a logistic model with each trial as controlling factor and the treatment as final factor will also beperformed.

UR - http://www.scopus.com/inward/record.url?scp=33746379119&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746379119&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33746379119

VL - 18

SP - 87

JO - Italian Journal of Neurological Sciences

JF - Italian Journal of Neurological Sciences

SN - 0392-0461

IS - 4

ER -